Atopic Dermatitis

Late-breaking positive phase 2a results were presented at AAD 2023.

Although the ingredient is widely used in skincare, the American Contact Dermatitis Society (ACDS) wants clinicians to take special considerations when patch testing for lanolin contact allergy.

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

The study also found lasting benefits of the supplement for bone density up to age 4.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

Results from the phase 3 study were presented at an AAD late-breaking research session.

This question drummed up discussion during one AAD 2023 session on the topic. We want to hear from you!

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

An AAD 2023 poster presentation reviewed the long-term safety periods of the TruE-AD1 and TRuE-AD2 trials.

Atopic Dermatitis treatment and management options are explored at several sessions conducted by Peter Lio, MD, FAAD, at AAD 2023.

The latest phase 3 trial results were showcased in an AAD late-breaking research session.

Can dietary modifications really improve dermatological conditions?

Dermavant’s ADORING 2 phase 3 trial met all primary and secondary endpoints.

Treatment safety and efficacy for atopic dermatitis has seen significant growth over the last decade.

Researchers reviewed nearly 7 years' worth of patch testing data to analyze trends in hand eczema in Latin America.

In this episode, Mona Shahriari, MD, discusses what dermatologists and patients with atopic dermatitis can expect as we transition from winter to spring, as well as new and emerging treatments and technologies for managing atopic dermatitis that she’s looking ahead to as the year progresses.

A group of dermatologists and dermatology students studied why AD may be related to certain cardiovascular diseases, neuropsychiatric diseases, autoimmune diseases, and obesity.

To date, publications about health care disparities in atopic dermatitis in Latin American countries are few and far between.

Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.

Researchers link proximity to heavy traffic and risk of atopic dermatitis in new study.

Patients suffering from atopic dermatitis may suffer more during the cold, dry winter month. Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine in Baltimore, Maryland, explores various treatment options that will add moisture back into the skin during seasonal flare-ups.

Adolescents and adults with seborrheic dermatitis may have a new topical treatment soon.

Research published in JAMA Dermatology finds dupilumab works quickly and safely for patients with erythrodermic atopic dermatitis.

Alexis shares take-home points from his popular sessions at South Beach Symposium.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, talk about how clinical approaches and understanding of risk/benefit profiles are evolving in light of the emerging long-term data.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the impact of the open-label extension data on the current atopic dermatitis landscape.

Matt Zirwas, MD, shares tips on diagnosing various forms of hand dermatitis and what patients can do to relieve symptoms of dermatitis at Maui Derm Hawaii 2023.

Thought leaders discuss the importance of rapid onset of action in atopic dermatitis care amid the backdrop of compelling 4-year efficacy and safety data for dupilumab.